JPMorgan downgraded Pacs Group (PACS) to Neutral from Overweight with an $18 price target The firm moved to the sidelines after the company postponed its Q3 earnings and said it received civil investigative demands from the federal government regarding its reimbursement and referral practices. This has created a prolonged overhang on the stock, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACS:
- PACS Group Inc options imply 6.6% move in share price post-earnings
- PACS Group Inc options imply 5.6% move in share price post-earnings
- PACS Group Inc options imply 9.7% move in share price post-earnings
- PACS Group Inc options imply 11.2% move in share price post-earnings
- Shareholder Alert for PACS Group, Inc. (NYSE:PACS)